Mostrando 10 resultados de: 12
Filtros aplicados
Subtipo de publicación
Article(12)
Publisher
CNS and Neurological Disorders - Drug Targets(1)
Colloids and Surfaces B: Biointerfaces(1)
International Journal of Molecular Sciences(1)
International Journal of Pharmaceutics(1)
Journal of Controlled Release(1)
Área temáticas
Farmacología y terapéutica(11)
Enfermedades(8)
Medicina y salud(6)
Cirugía y especialidades médicas afines(1)
Fisiología humana(1)
Área de conocimiento
Nanopartícula(4)
Biotecnología(3)
Descubrimiento de fármacos(2)
Neurología(2)
Biomateriales(1)
Origen
scopus(12)
Comparative study of Ex Vivo transmucosal permeation of pioglitazone nanoparticles for the treatment of Alzheimer's disease
ArticleAbstract: Pioglitazone has been reported in the literature to have a substantial role in the improvement of ovPalabras claves:Alzheimer's disease, Nanoparticles, Pioglitazone, PLGA-PEG, Transmucosal permeationsAutores:Calpena A.C., Espina M., García M.L., Halbaut L., Lupe Carolina Espinoza, Silva-Abreu M.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDevelopment of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: In vitro and Ex vivo characterization
ArticleAbstract: Background: Donepezil (DPZ) is widely prescribed as a specific and reversible acetylcholinesterase iPalabras claves:Alzheimer’s disease, Delivery systems, Donepezil, Intranasal route, Microemulsion, permeationAutores:Calpena A.C., Clares-Naveros B., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Vacacela M.Fuentes:scopusArticle dexibuprofen biodegradable nanoparticles: One step closer towards a better ocular interaction study
ArticleAbstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect variousPalabras claves:Dexibuprofen, Drug delivery system, Nanoparticles, PLGAAutores:Alsafi Z., Antoni Camins, Calpena A.C., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Muñoz M., Ortiz A., Prat J., Pujol M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusDiscovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice
ArticleAbstract: The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaPalabras claves:Autores:Andrisano V., Antoni Camins, Bartolini M., Brazzolotto X., Cieslikiewicz-Bouet M., Cisternas P., Colletier J.P., Coquelle N., De Simone A., Ettcheto M., Firuzi O., García M.L., Inestrosa N.C., Jean L., Muñoz-Torrero D., Nachon F., Oliva C.A., Perez B., Pons M., Renard P.Y., Rendina M., Ricchini M., Sanchez-Lopez E., Saso L., Silman I., Viayna E.Fuentes:scopusHuman skin permeation studies with PPARγ agonist to improve its permeability and efficacy in inflammatory processes
ArticleAbstract: Rosacea is the most common inflammatory skin disease. It is characterized by erythema, inflammatoryPalabras claves:inflammation, limonene, Pioglitazone, PPAR-γ, ROSÁCEA, Skin permeationAutores:Calpena A.C., Espina M., Fábrega M.J., García M.L., Lupe Carolina Espinoza, Rodríguez-Lagunas M.J., Silva-Abreu M.Fuentes:scopusPEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization
ArticleAbstract: Dexibuprofen-loaded PEGylated PLGA nanospheres have been developed to improve the biopharmaceuticalPalabras claves:Dexibuprofen, drug delivery, inflammation, Nanospheres, PEG, PLGAAutores:Antoni Camins, Calpena A.C., Cano A., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopusIn vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration
ArticleAbstract: Pranoprofen (PF) is a NSAID considered as a safe anti-inflammatory treatment for strabismus and/or cPalabras claves:Anti-inflammatory efficacy, Corneal permeation, Cytotoxicity cell, Nanoparticles, Poly (lactic/glycolic) acid (PLGA), PranoprofenAutores:Abrego G., Alvarado H., Calpena A.C., Cristina Cañadas, García M.L., Silva A.M., Souto E.M.B.Fuentes:scopus